title: Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders.
abstract: OBJECTIVE
  A new family of prostaglandin F2 isomers called F2-isoprostanes, produced by free radical peroxidation of arachidonic acid, has recently been described in vivo. Its quantification has been suggested to be a reliable measure of oxidant injury in vivo. The purpose of this study was to investigate urinary F2-isoprostane formation as an index of lipid peroxidation in scleroderma spectrum disorders.
  
  
  METHODS
  Urine samples were obtained from 52 patients with systemic sclerosis (SSc; n = 37) or undifferentiated connective tissue diseases (UCTD; n = 15) and from 20 healthy volunteers. Urinary isoprostaglandin F2alpha type III (iPF2alpha-III) and 11-dehydro thromboxane B2 (11-dehydroTXB2) concentrations were determined using enzyme immunoassays.
  
  
  RESULTS
  The urinary concentration of iPF2alpha-III was approximately twice as high in patients (mean +/- SEM 229+/-16 pmoles/mmoles creatinine) as in controls (116+/-9 pmoles/mmoles creatinine) (P < 0.0001). However, the urinary concentration of iPF2alpha-III was not significantly different among patients with UCTD, limited SSc, and diffuse SSc (mean +/- SEM 221+/-27 versus 245+/-32 versus 220+/-25 pmoles/mmoles creatinine, respectively). No significant correlation was found between the urinary concentrations of iPF2alpha-III and 11-dehydroTXB2.
  
  
  CONCLUSIONS
  This study provides evidence of enhanced lipid peroxidation in both SSc and UCTD, and suggests a rationale for antioxidant treatment of SSc. Formation of F2-isoprostanes has to be investigated as a means for the evaluation of such therapy.
authors.affiliation: Grenoble University School of Medicine, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Cracowski
authors.forename: C
authors.initials: C
authors.lastname: Marpeau
authors.forename: P H
authors.initials: PH
authors.lastname: Carpentier
authors.forename: B
authors.initials: B
authors.lastname: Imbert
authors.forename: M
authors.initials: M
authors.lastname: Hunt
authors.forename: F
authors.initials: F
authors.lastname: Stanke-Labesque
authors.forename: G
authors.initials: G
authors.lastname: Bessard
mesh_terms: D000328:Adult; D000368:Aged; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D028441:F2-Isoprostanes; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000276:immunology / Q000652:urine*; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine
chemical_list: D028441:F2-Isoprostanes; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D015237:Dinoprost